Lee's Pharmaceutical Holdings (STU:L1PA) Total Liabilities : €109.6 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lee's Pharmaceutical Holdings Total Liabilities?

Lee's Pharmaceutical Holdings's Total Liabilities for the quarter that ended in Jun. 2024 was €109.6 Mil.

Lee's Pharmaceutical Holdings's quarterly Total Liabilities declined from Jun. 2023 (€117.97 Mil) to Dec. 2023 (€109.21 Mil) but then increased from Dec. 2023 (€109.21 Mil) to Jun. 2024 (€109.60 Mil).

Lee's Pharmaceutical Holdings's annual Total Liabilities declined from Dec. 2021 (€141.36 Mil) to Dec. 2022 (€113.92 Mil) and declined from Dec. 2022 (€113.92 Mil) to Dec. 2023 (€109.21 Mil).

Lee's Pharmaceutical Holdings Total Liabilities Historical Data

The historical data trend for Lee's Pharmaceutical Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lee's Pharmaceutical Holdings Total Liabilities Chart

Lee's Pharmaceutical Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

120.62

141.36

113.92

109.21

131.33

Lee's Pharmaceutical Holdings Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial															113.92	117.97	109.21	109.60	131.33

Lee's Pharmaceutical Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Lee's Pharmaceutical Holdings's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	76.182	+	(8.756	+	8.622
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	12.928	+	2.718)
	=	109.2

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	339.412	-	230.207
	=	109.2

Lee's Pharmaceutical Holdings's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	75.253	+	(9.337	+	8.576
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	13.796	+	2.718)
	=	109.6

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	303.169	-	193.565
	=	109.6

Lee's Pharmaceutical Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Lee's Pharmaceutical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (STU:L1PA) » Definitions » Total Liabilities

Traded in Other Exchanges

00950:Hong Kong

Address

Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG

Website

https://www.leespharm.com

Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

Lee's Pharmaceutical Holdings Headlines

No Headlines